Anthrax vaccine adsorbed (BioThrax) - Emergent BioSolutions

Drug Profile

Anthrax vaccine adsorbed (BioThrax) - Emergent BioSolutions

Alternative Names: Anthrax vaccine adsorbed (AVA) - Emergent BioSoutions; AVA; BaciThrax; BioThrax

Latest Information Update: 16 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Emergent BioSolutions
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anthrax

Most Recent Events

  • 09 May 2018 Biomedical Advanced Research and Development Authority and Rho, Inc. plans the B-SAFE phase II trial for Anthrax in the US , (NCT03518125)
  • 21 Apr 2018 Adverse events data from a phase II trial in Anthrax presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 12 Apr 2018 Preregistration (Mutual Recognition Procedure) for Anthrax (Prevention) in France, United Kingdom, Poland, Netherlands, Italy (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top